April 20, 2017 / 11:14 AM / 8 months ago

BRIEF-Redhill Biopharma announces peer-reviewed publication of positive Yeliva® phase I study results in advanced solid tumors

April 20 (Reuters) - Redhill Biopharma Ltd

* Redhill biopharma announces peer-reviewed publication of the positive yeliva® phase i study results in advanced solid tumors

* Redhill biopharma ltd says phase i study with yeliva(®) in patients with advanced solid tumors successfully met its primary and secondary endpoints

* Redhill biopharma ltd says results demonstrated that drug is well-tolerated and can be safely administered to cancer patients in study

* Redhill biopharma ltd says is pursuing several phase i/ii clinical studies with yeliva, targeting multiple oncology and inflammatory indications

* Redhill biopharma -phase ii study to evaluate efficacy of yeliva in patients with moderate to severe ulcerative colitis is to be initiated in h2 of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below